These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19422478)

  • 1. Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.
    Puoti C; Pellicelli AM; Romano M; Mecenate F; Guarisco R; Barbarini G; Mazzoni E; Spilabotti L; Bellis L; Paglia F; Barlattani A; Picardi A; Paffetti A; Bonaventura ME; Nosotti L; Mitidieri O; Dell'Unto O; Villani R; Dell'Unto C; Morrone A; Soccorsi F;
    Liver Int; 2009 Nov; 29(10):1479-84. PubMed ID: 19422478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.
    Ferenci P; Laferl H; Scherzer TM; Gschwantler M; Maieron A; Brunner H; Stauber R; Bischof M; Bauer B; Datz C; Löschenberger K; Formann E; Staufer K; Steindl-Munda P;
    Gastroenterology; 2008 Aug; 135(2):451-8. PubMed ID: 18503773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study.
    Puoti C; Barbarini G; Picardi A; Romano M; Pellicelli A; Barlattani A; Mecenate F; Guarisco R; Costanza OM; Spilabotti L; Bellis L; Bonaventura ME; Dell' Unto O; Elmo MG; Nicolini AM; Nosotti L; Soccorsi F;
    J Viral Hepat; 2011 Jun; 18(6):393-9. PubMed ID: 20546499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
    Calleja JL; García-Samaniego J; Ruiz-Antorán B; Trapero M; Morillas R; de la Revilla J; Erdozaín JC; Espinosa MD; Suárez D; Solá R; Romero-Gómez M; Baños F; Alvarez MA;
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1705-10. PubMed ID: 22742958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
    Yu JW; Sun LJ; Zhao YH; Kang P; Gao J; Li SC
    Liver Int; 2009 Nov; 29(10):1485-93. PubMed ID: 19602134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of Peg-Interferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection.
    Yeh ML; Hsieh MY; Huang CI; Huang CF; Hsieh MH; Huang JF; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2016 Apr; 31(4):835-41. PubMed ID: 26478984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.
    Marcellin P; Reau N; Ferenci P; Hadziyannis S; Messinger D; Tatsch F; Jensen D
    J Hepatol; 2012 Jun; 56(6):1276-82. PubMed ID: 22314423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.
    Hiramatsu N; Inoue Y; Oze T; Kurashige N; Yakushijin T; Mochizuki K; Miyagi T; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Hayashi N
    J Gastroenterol; 2011 Nov; 46(11):1335-43. PubMed ID: 21858637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.
    Zeuzem S; Diago M; Gane E; Reddy KR; Pockros P; Prati D; Shiffman M; Farci P; Gitlin N; O'Brien CB; Lamour F; Lardelli P;
    Gastroenterology; 2004 Dec; 127(6):1724-32. PubMed ID: 15578510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
    Cheng WS; Roberts SK; McCaughan G; Sievert W; Weltman M; Crawford D; Rawlinson W; Marks PS; Thommes J; Rizkalla B; Yoshihara M; Dore GJ;
    J Hepatol; 2010 Oct; 53(4):616-23. PubMed ID: 20619475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
    Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.
    Weiland O; Hollander A; Mattsson L; Glaumann H; Lindahl K; Schvarcz R; Lindh G; Enquist R; Quist A
    J Viral Hepat; 2008 Sep; 15(9):641-5. PubMed ID: 18507753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
    Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
    Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients.
    Tural C; Galeras JA; Planas R; Coll S; Sirera G; Giménez D; Salas A; Rey-Joly C; Cirera I; Márquez C; Tor J; Videla S; García-Retortillo M; Clotet B; Solà R
    Antivir Ther; 2008; 13(8):1047-55. PubMed ID: 19195330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.